Ascentage Pharma Group Inc.
Quick facts
Marketed products
- Azacitidine Injection · Oncology
Azacitidine is a DNA methyltransferase inhibitor that causes hypomethylation of DNA and promotes differentiation and apoptosis of abnormal hematopoietic cells. - Rd · Oncology
Rd is a BCL-2 family protein inhibitor that promotes apoptosis in cancer cells by blocking anti-apoptotic proteins.
Phase 3 pipeline
- APG-2575(Lisaftoclax ) · Oncology
APG-2575 (Lisaftoclax) is a BCL-2 family protein inhibitor that promotes apoptosis by blocking anti-apoptotic proteins in cancer cells. - Lisaftoclax (APG-2575) · Oncology
Lisaftoclax is a BCL-2 family protein inhibitor that promotes apoptosis by blocking anti-apoptotic proteins in cancer cells. - lisaftoclax +BTK inhibitor · Oncology
Lisaftoclax is a BCL-2 inhibitor combined with a BTK inhibitor to promote apoptosis in cancer cells while blocking B-cell survival signaling.
Phase 2 pipeline
- APG-115 · Oncology
APG-115 is a small molecule inhibitor of BCL-2 family proteins. - APG2575
- HQP1351
- Hydroxyurea or Interferon-based therapy
- Imatinib, Dasatinib or Nilotinib
Phase 1 pipeline
- [14C ]APG-2575
- [14C] HQP1351
- APG-1252 · Oncology
APG-1252 is a Bcl-2 and Bcl-xL inhibitor that induces apoptosis in cancer cells. - APG 2575 ramp up arm
- APG-3288
- APG-5918
- Ascentage Pharma HQP1351 bioavailable inhibitor
- Reduced-dose HHT
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: